Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRB-601 Monotherapy and Combination in Advanced Solid Tumors
NCT06603844Phase 2Recruiting
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of CRB-601 in solid tumor, sponsored by Corbus Pharmaceuticals Holdings, Inc.. Started Dec 2024; status: recruiting.
02
Drugs
CRB-601
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06603844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603844.